{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:45:24Z","timestamp":1790091924982,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Jinhua Science and Technology Plan Project","award":["2023-4-080"],"award-info":[{"award-number":["2023-4-080"]}]},{"name":"Zhumadian City Science and Technology Innovation Youth Project","award":["QNZX202302"],"award-info":[{"award-number":["QNZX202302"]}]},{"name":"Natural Science Foundation of Henan Province project","award":["252300421674"],"award-info":[{"award-number":["252300421674"]}]},{"name":"National Scientific Research Project Cultivation Fund Project of Huanghuai University","award":["XKPY-2024013"],"award-info":[{"award-number":["XKPY-2024013"]}]},{"name":"the Support Program for Young Backbone Teachers of Huanghuai University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s15010-026-02739-5","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T10:00:29Z","timestamp":1770631229000},"page":"1105-1116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Emerging resistance to imipenem-relebactam among enterobacterales and non-fermenting gram-negative bacilli: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"54","author":[{"given":"Mengyu","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Qiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"2739_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.823684","volume":"12","author":"S-S Jean","year":"2022","unstructured":"Jean S-S, Harnod D, Hsueh P-R. Global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684.","journal-title":"Front Cell Infect Microbiol"},{"key":"2739_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.12.002","author":"S Vasoo","year":"2015","unstructured":"Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician. Mayo Clin Proc. 2015. https:\/\/doi.org\/10.1016\/j.mayocp.2014.12.002.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"2739_CR3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s15010-024-02342-6","volume":"53","author":"R Casale","year":"2025","unstructured":"Casale R, Boattini M, Comini S, Bastos P, Corcione S, De Rosa FG, et al. Clinical and microbiological features of positive blood culture episodes caused by non-fermenting gram-negative bacilli other than Pseudomonas and Acinetobacter species (2020\u20132023). Infection. 2025;53(1):183\u201396.","journal-title":"Infection"},{"issue":"Supplement_4","key":"2739_CR4","doi-asserted-by":"publisher","first-page":"iv38","DOI":"10.1093\/jac\/dkab353","volume":"76","author":"E Bouza","year":"2021","unstructured":"Bouza E. The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections. J Antimicrob Chemother. 2021;76(Supplement_4):iv38\u201345.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2739_CR5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1089\/mdr.2015.0220","volume":"22","author":"E Cerceo","year":"2016","unstructured":"Cerceo E, Deitelzweig SB, Sherman BM, Amin AN. Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist. 2016;22(5):412\u201331.","journal-title":"Microb Drug Resist"},{"issue":"7","key":"2739_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00256-22","volume":"66","author":"JN O'Donnell","year":"2022","unstructured":"O\u2019Donnell JN, Lodise TP. New perspectives on antimicrobial agents: imipenem-relebactam. Antimicrob Agents Chemother. 2022;66(7):e00256-22.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2739_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/phar.2378","volume":"40","author":"JR Smith","year":"2020","unstructured":"Smith JR, Rybak JM, Claeys KC. Imipenem\u2010cilastatin\u2010relebactam: a novel \u03b2\u2010lactam\u2013\u03b2\u2010lactamase inhibitor combination for the treatment of multidrug\u2010resistant gram\u2010negative infections. Pharmacotherapy. 2020;40(4):343\u201356.","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2739_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11050628","volume":"11","author":"P Gaibani","year":"2022","unstructured":"Gaibani P, Giani T, Bovo F, Lombardo D, Amadesi S, Lazzarotto T, et al. Resistance to ceftazidime\/avibactam, meropenem\/vaborbactam and imipenem\/relebactam in gram-negative MDR bacilli: molecular mechanisms and susceptibility testing. Antibiotics. 2022;11(5):628.","journal-title":"Antibiotics"},{"key":"2739_CR9","unstructured":"Wayne A. Clinical and Laboratory Standards Institute; CLSI. 2022. Performance standards for antimicrobial susceptibility testing 20th Informational Supplement CLSI document. 2022."},{"key":"2739_CR10","unstructured":"EUCAST T. European committee on antimicrobial susceptibility testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters Version 100. 2020."},{"issue":"3","key":"2739_CR11","first-page":"40","volume":"7","author":"G Schwarzer","year":"2007","unstructured":"Schwarzer G. meta: an R package for meta-analysis. R News. 2007;7(3):40\u20135.","journal-title":"R News"},{"key":"2739_CR12","unstructured":"Team RCJhwR-po. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013."},{"issue":"6","key":"2739_CR13","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10096-022-04452-1","volume":"41","author":"V Ad\u00e1mkov\u00e1","year":"2022","unstructured":"Ad\u00e1mkov\u00e1 V, Marekovi\u0107 I, Szab\u00f3 J, Pojnar L, Billov\u00e1 S, Horvat Herceg S, et al. Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019. Eur J Clin Microbiol Infect Dis. 2022;41(6):989\u201396.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2739_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00535-19","author":"TE Asempa","year":"2019","unstructured":"Asempa TE, Nicolau DP, Kuti JL. Carbapenem-nonsusceptible Pseudomonas aeruginosa isolates from intensive care units in the United States: a potential role for new \u03b2-lactam combination agents. J Clin Microbiol. 2019. https:\/\/doi.org\/10.1128\/jcm.00535-19.","journal-title":"J Clin Microbiol"},{"issue":"6","key":"2739_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.867","volume":"27","author":"A Bittencourt","year":"2024","unstructured":"Bittencourt A, Faustino V, de Mendon\u00e7a Batista P, Paula M, Polis T. EPH38 antimicrobial susceptibility of Klebsiella pneumoniae clinical isolates from the lower respiratory tract infection during the COVID-19 pandemic in Brazil (SMART 2020-2021). Value Health. 2024;27(6):S160.","journal-title":"Value Health"},{"key":"2739_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02165-19","author":"PA Fraile-Ribot","year":"2020","unstructured":"Fraile-Ribot PA, Zamorano L, Orellana R, del Barrio-Tofi\u00f1o E, S\u00e1nchez-Diener I, Cortes-Lara S, et al. Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants. Antimicrob Agents Chemotherap. 2020. https:\/\/doi.org\/10.1128\/aac.02165-19.","journal-title":"Antimicrob Agents Chemotherap"},{"key":"2739_CR17","first-page":"1838","volume-title":"Activity of imipenem-relebactam (MK-7655) against enterobacteriaceae and pseudomonas aeruginosa from intraabdominal infections in North America\u2014SMART 2015","author":"M Hackel","year":"2016","unstructured":"Hackel M, Young K, Motyl M, Sahm D. Activity of imipenem-relebactam (MK-7655) against enterobacteriaceae and pseudomonas aeruginosa from intraabdominal infections in North America\u2014SMART 2015. Open Forum Infectious Diseases: Oxford University Press; 2016. p. 1838."},{"issue":"7","key":"2739_CR18","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1093\/jac\/dky107","volume":"73","author":"JA Karlowsky","year":"2018","unstructured":"Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, et al. In vitro activity of imipenem\/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J Antimicrob Chemother. 2018;73(7):1872\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"2739_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00169-18","author":"JA Karlowsky","year":"2018","unstructured":"Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem-relebactam against clinical isolates of Gram-negative bacilli isolated in hospital laboratories in the United States as part of the SMART 2016 program. Antimicrob Agents Chemother. 2018. https:\/\/doi.org\/10.1128\/aac.00169-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"2739_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jgar.2019.10.028","volume":"21","author":"JA Karlowsky","year":"2020","unstructured":"Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF. In vitro activity of imipenem\/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015\u20132017. J Glob Antimicrob Resist. 2020;21:223\u20138.","journal-title":"J Glob Antimicrob Resist"},{"issue":"3","key":"2739_CR21","first-page":"dlae077","volume":"6","author":"JA Karlowsky","year":"2024","unstructured":"Karlowsky JA, Lob SH, Siddiqui F, Polis T, Vallejo JL, Young K, et al. Activity of ceftolozane\/tazobactam and imipenem\/relebactam against Gram-negative clinical isolates collected in Mexico\u2014SMART 2017\u20132021. JAC-Antimicrob Resis. 2024;6(3):dlae077.","journal-title":"JAC-Antimicrob Resis"},{"key":"2739_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jgar.2018.07.012","volume":"15","author":"JA Karlowsky","year":"2018","unstructured":"Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF. Activity of imipenem\/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015\u20132016. J Glob Antimicrob Resist. 2018;15:140\u20137.","journal-title":"J Glob Antimicrob Resist"},{"key":"2739_CR23","doi-asserted-by":"crossref","unstructured":"Lob S, Hackel M, Siddiqui F, Bauer KA, DeRyke CA, Young K, et al. 1671. Activity of imipenem\/relebactam and comparators against gram-negative MDR and DTR pathogens from patients with respiratory and bloodstream infections\u2013SMART United States 2018\u20132020. Open Forum Infectious Diseases: Oxford University Press US; 2022. p. ofac492. 1301.","DOI":"10.1093\/ofid\/ofac492.1301"},{"key":"2739_CR24","unstructured":"Lob S, Wise MG, Bauer K, Siddiqui F, Hilbert DW, Esterly J, et al. 2154. Cross-resistance of ceftolozane-tazobactam and imipenem-relebactam against clinical P. aeruginosa isolates from bloodstream and respiratory tract infections\u2013SMART United States 2019\u20132021. Open Forum Infectious Diseases: Oxford University Press US; 2023. p. ofad500. 1777."},{"key":"2739_CR25","doi-asserted-by":"crossref","unstructured":"Lob SH, DePestel DD, DeRyke CA, Kazmierczak KM, Young K, Motyl MR, et al. Ceftolozane\/tazobactam and imipenem\/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards\u2014SMART United States 2017\u20132019. Open Forum Infectious Diseases: Oxford University Press US; 2021. p. ofab320.","DOI":"10.1093\/ofid\/ofab320"},{"issue":"2","key":"2739_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2017.02.018","volume":"88","author":"SH Lob","year":"2017","unstructured":"Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, et al. In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015\u2013Results from the SMART global surveillance program. Diagn Microbiol Infect Dis. 2017;88(2):171\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"2739_CR27","doi-asserted-by":"publisher","first-page":"e00920","DOI":"10.1128\/aac.00920-23","volume":"67","author":"VH Ruiz","year":"2023","unstructured":"Ruiz VH, Fratoni A, Nicolau DP, Kuti JL. In vitro activity of imipenem\/relebactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Antimicrob Agents Chemother. 2023;67(11):e00920-e923.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"2739_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10096-021-04363-7","volume":"41","author":"HS Sader","year":"2022","unstructured":"Sader HS, Carvalhaes CG, Shortridge D, Castanheira M. Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020. Eur J Clin Microbiol Infect Dis. 2022;41(2):319\u201324.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"2739_CR29","doi-asserted-by":"publisher","first-page":"6393","DOI":"10.1128\/AAC.01125-16","volume":"60","author":"DR Snydman","year":"2016","unstructured":"Snydman DR, Jacobus NV, McDermott LA. In vitro evaluation of the activity of imipenem-relebactam against 451 recent clinical isolates of Bacteroides group and related species. Antimicrob Agents Chemother. 2016;60(10):6393\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2739_CR30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1017\/ice.2022.161","volume":"44","author":"PD Tamma","year":"2023","unstructured":"Tamma PD, Bergman Y, Jacobs EB, Lee JH, Lewis S, Cosgrove SE, et al. Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates. Infect Control Hosp Epidemiol. 2023;44(5):762\u20137.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2739_CR31","doi-asserted-by":"crossref","unstructured":"Wise MG, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, et al. Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane\/tazobactam, imipenem\/relebactam and comparators: SMART 2018\u201322. JAC-Antimicrobial Resistance. 2024;6(5):dlae150.","DOI":"10.1093\/jacamr\/dlae150"},{"issue":"3","key":"2739_CR32","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jfma.2023.09.006","volume":"123","author":"MG Wise","year":"2024","unstructured":"Wise MG, Karlowsky JA, Chen W-T, Siddiqui F, Young K, Motyl MR, et al. Susceptibility of gram-negative isolates collected in Taiwan to imipenem\/relebactam and comparator agents\u2013SMART 2018\u20132021. J Formos Med Assoc. 2024;123(3):400\u20137.","journal-title":"J Formos Med Assoc"},{"issue":"7","key":"2739_CR33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1017\/ice.2022.185","volume":"44","author":"HL Zhang","year":"2023","unstructured":"Zhang HL, Gontjes KJ, Han JH, Alby K, Lapp Z, Snitkin E, et al. Characterization of resistance to newer antimicrobials among carbapenem-resistant Klebsiella pneumoniae in the post\u2013acute-care setting. Infect Control Hosp Epidemiol. 2023;44(7):1159\u201362.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"2739_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050528","volume":"14","author":"I Karaiskos","year":"2025","unstructured":"Karaiskos I, Galani I, Daikos GL, Giamarellou H. Breaking through resistance: a comparative review of new beta-lactamase inhibitors (Avibactam, Vaborbactam, Relebactam) against multidrug-resistant superbugs. Antibiotics (Basel). 2025;14(5):528.","journal-title":"Antibiotics (Basel)"},{"issue":"7","key":"2739_CR35","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s10096-024-04756-4","volume":"43","author":"JA Karlowsky","year":"2024","unstructured":"Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, et al. Activity of ceftolozane\/tazobactam and imipenem\/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy\u2014SMART 2017\u20132021. Eur J Clin Microbiol Infect Dis. 2024;43(7):1343\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"2739_CR36","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02235-21","volume":"10","author":"D Kurihara","year":"2022","unstructured":"Kurihara D, Matsumoto S, Kishi N, Ishii Y, Mori M. In vitro antibacterial activity of imipenem\/relebactam against clinical isolates in Japan. Microbiol Spectr. 2022;10(2):e02235-21.","journal-title":"Microbiol Spectr"},{"issue":"6","key":"2739_CR37","doi-asserted-by":"publisher","first-page":"668","DOI":"10.37201\/req\/102.2021","volume":"34","author":"M Pe\u00f1uelas","year":"2021","unstructured":"Pe\u00f1uelas M, Garc\u00eda-Salguero C, I\u00f1igo M, Vi\u00f1uela-Prieto JM, Candel FJ, del Pozo JL, et al. In vitro activity of imipenem\/relebactam against Gram-negative clinical isolates in two Spanish tertiary hospitals. Rev Esp Quimioter. 2021;34(6):668.","journal-title":"Rev Esp Quimioter"},{"key":"2739_CR38","doi-asserted-by":"crossref","unstructured":"Yang Q, Zhang H, Yu Y, Kong H, Duan Q, Wang Y, et al. In vitro activity of imipenem\/relebactam against Enterobacteriaceae isolates obtained from intra-abdominal, respiratory tract, and urinary tract infections in China: study for monitoring antimicrobial resistance trends (SMART), 2015\u20132018. Clinical Infectious Diseases. 2020;71(Supplement_4):S427-S35.","DOI":"10.1093\/cid\/ciaa1519"},{"key":"2739_CR39","unstructured":"Freed J, Shawn, Hanson ND. AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem\/relebactam susceptibility. Microbiology spectrum. 2024;12(11):e00142\u201324."},{"issue":"1","key":"2739_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19642-y","volume":"15","author":"AH El-Ashry","year":"2025","unstructured":"El-Ashry AH, Abdrabou AM, El-Tantawy N, Mahmoud R, El-Mahdy R. In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii. Sci Rep. 2025;15(1):34109.","journal-title":"Sci Rep"},{"issue":"2","key":"2739_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3103\/S0891416824700198","volume":"39","author":"A Tozluyurt","year":"2024","unstructured":"Tozluyurt A. The effectiveness of aztreonam, aztreonam-avibactam, cefiderocol on bla NDM-producing E. coli isolates. Mol Genet Microbiol Virol. 2024;39(2):158\u201364.","journal-title":"Mol Genet Microbiol Virol"},{"issue":"6","key":"2739_CR42","volume":"7","author":"J Halim","year":"2025","unstructured":"Halim J, Bouzo J, Carabetta VJ. Evaluation of sulbactam\/durlobactam activity and synergy against highly drug-resistant Acinetobacter baumannii strains. JAC-Antimicrob Resis. 2025;7(6):dlaf220.","journal-title":"JAC-Antimicrob Resis"},{"issue":"1","key":"2739_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.51585\/gjm.2024.1.0028","volume":"4","author":"A Tozluyur","year":"2024","unstructured":"Tozluyur A. Fosfomycin in the treatment of New Delhi Metallo-\u03b2-Lactamase-5 (blaNDM-5)-producing Escherichia coli infection. Germ J Microbiol. 2024;4(1):1\u20135.","journal-title":"Germ J Microbiol"},{"issue":"4","key":"2739_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106744","volume":"61","author":"HS Sader","year":"2023","unstructured":"Sader HS, Mendes RE, Arends SR, Carvalhaes CG, Shortridge D, Castanheira M. Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020\u20132021). Int J Antimicrob Agents. 2023;61(4):106744.","journal-title":"Int J Antimicrob Agents"},{"key":"2739_CR45","doi-asserted-by":"crossref","unstructured":"Agyeman WY, Bisht A, Gopinath A, Cheema AH, Chaludiya K, Khalid M, et al. A systematic review of antibiotic resistance trends and treatment options for hospital-acquired multidrug-resistant infections. Cureus. 2022;14(10).","DOI":"10.7759\/cureus.29956"},{"key":"2739_CR46","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0068-2022","author":"D Reynolds","year":"2022","unstructured":"Reynolds D, Burnham JP, Guillamet CV, McCabe M, Yuenger V, Betthauser K, et al. The threat of multidrug-resistant\/extensively drug-resistant Gram-negative respiratory infections: another pandemic. Eur Respir Rev. 2022. https:\/\/doi.org\/10.1183\/16000617.0068-2022.","journal-title":"Eur Respir Rev"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02739-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02739-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:48:31Z","timestamp":1782920911000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02739-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2739"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02739-5","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"20 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that generative artificial intelligence (AI) tools were used solely to improve the language quality and structural clarity of the manuscript. The AI tools did not generate any original scientific content, data, analysis, or interpretations. All intellectual content, results, and conclusions are entirely the authors' own work. The authors thoroughly reviewed and edited all AI-assisted outputs to ensure accuracy and appropriateness.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI use"}}]}}